Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders
Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders: Allogeneic umbilical cord blood transplantation as a standard treatment for underlying hematological diseases.
Study summary
The primary objective is to investigate the correlation between specific patterns of γδ T cell reconstitution after umbilical cord blood transplantation and key clinical outcomes.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* 1: Patients undergo their first unrelated cord blood transplantation (UCBT) at our institution.
2: Diagnosis of a hematologic malignancy or disorder eligible for UCBT (e.g., acute leukemia, myelodysplastic syndrome, severe aplastic anemia)
3: Willing and able to provide written informed consent.
4: No restrictions on gender, age, or race.
Exclusion Criteria:
* Participation in an interventional clinical trial investigating prophylactic donor-derived cell infusion (e.g., DLI, MSC) during the study period.
Primary outcome measure(s)
Reconstitution level of γδ T cells — 1 year The reconstitution level of γδ T cells in peripheral blood will be measured by flow cytometry at 1, 2, 3, 6, 9, and 12 months after umbilical cord blood transplantation. The outcome is measured as the absolute cell count per microliter of blood and/or the percentage of γδ T cells within total lymphocytes.
Trial sites (1)
Facility
City
Region
Status
the First Affiliated Hospital of University of Science and Technology of China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.